No results for ‘’
Sun Pharma Advanced Research Company Ltd
₹204.22
(0.83%)
Fri, 12 Jun 2026, 03:02 pm
Health Technology
Pharmaceuticals: Major
24.5KSun Pharma Advanced Research Company PE Ratio
| Particulars | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 113.91 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price to book ratio | 0 | 38.86 | 30.51 | 146.12 | 265.18 | 0 | 24.82 | 24.77 | 116.67 | 227.92 | 49.44 | 51.40 | 16.98 | 0 | 0 | 258.46 | 11.36 | 95.47 | 0 |
| Price to sales ratio | 0 | 44.71 | 30.97 | 60.02 | 25.56 | 53.36 | 28.39 | 20.66 | 74.76 | 42.26 | 43.07 | 119.94 | 26.84 | 32.92 | 14.68 | 56.91 | 21.40 | 158.92 | 66.92 |
| Price to cash flow ratio | 0 | 0 | 43.05 | 164.25 | 538.66 | 0 | 0 | 114.37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Enterprise value | 0 | 1675Cr | 1090Cr | 2062Cr | 1493Cr | 1608Cr | 2455Cr | 3443Cr | 11629Cr | 6858Cr | 7719Cr | 9280Cr | 4698Cr | 2588Cr | 3934Cr | 7878Cr | 4722Cr | 11910Cr | 5070Cr |
| Enterprise value to EBITDA ratio | 0 | 81.59 | 0 | 0 | 0 | 0 | 0 | 101.89 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt to equity ratio | 0 | 0.01 | 0.05 | 0.15 | 1.17 | 0 | 0.75 | 0.04 | 0.04 | 1.86 | 0.02 | 0.01 | 0.01 | 0 | 0 | 2.54 | 0.03 | 0.49 | 0 |
| Return on equity % | 0 | -10.33 | -22.71 | -86.56 | -86.09 | 0 | -107.55 | 24.48 | -33.06 | -107.93 | -126.60 | -114.41 | -60.48 | -225.08 | 0 | 0 | -81.83 | -121.28 | 0 |
Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio
The Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio is a key financial metric used by investors to evaluate Sun Pharma Advanced Research Company Ltd's valuation, profitability, and overall financial performance. Tracking the Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Sun Pharma Advanced Research Company Ltd (NSE: SPARC, BSE: 532872) is currently trading at ₹204.22, with a market capitalization of ₹6678.65Cr. As a leading company in the Health technology sector and Pharmaceuticals: major industry, monitoring the Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio is essential for fundamental analysis.
Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio Current Value
The current Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio stands at 0.
The Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio remains stable, indicating consistent financial performance.
Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio Historical Trend
The Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio has shown the following historical trend:
- 2024: 0
- 2023: 0
- 2022: 0
- 2021: 0
- 2020: 0
The decline in Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio indicates improving financial efficiency or better earnings growth.
What Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio Indicates for Investors
The Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio plays a crucial role in understanding the company's financial health and valuation.
A higher P/E ratio indicates investors expect strong future earnings growth, while a lower ratio may signal undervaluation.
Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio Analysis Summary
The Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Sun Pharma Advanced Research Company Ltd Price to Earnings Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.